Skip to main content

Carcinoma, Intraductal, Noninfiltrating clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)

    open to eligible females ages 18 years and up

    This is a pilot study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to pembrolizumab.

    San Francisco, California

Last updated: